Translate Bio (NASDAQ:TBIO) had its target price hoisted by investment analysts at Leerink Swann from $24.00 to $25.00 in a research report issued on Wednesday. The firm presently has an “outperform” rating on the stock. Leerink Swann’s target price suggests a potential upside of 317.36% from the company’s previous close.
Several other research firms also recently commented on TBIO. Evercore ISI initiated coverage on shares of Translate Bio in a research note on Monday, July 23rd. They issued an “outperform” rating and a $25.00 price target on the stock. Citigroup initiated coverage on shares of Translate Bio in a research report on Monday, July 23rd. They set a “buy” rating and a $20.00 target price on the stock. Finally, ValuEngine raised shares of Translate Bio from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.
TBIO stock traded down $0.30 during trading on Wednesday, hitting $5.99. The company had a trading volume of 1,685 shares, compared to its average volume of 63,899. Translate Bio has a 52-week low of $5.00 and a 52-week high of $16.60. The company has a quick ratio of 1.69, a current ratio of 16.72 and a debt-to-equity ratio of 0.91.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Hong Kong Ltd purchased a new position in Translate Bio during the 2nd quarter valued at about $128,000. Bank of New York Mellon Corp purchased a new position in Translate Bio during the 3rd quarter valued at about $139,000. DAFNA Capital Management LLC purchased a new position in Translate Bio during the 2nd quarter valued at about $253,000. Dean Capital Investments Management LLC purchased a new position in Translate Bio during the 2nd quarter valued at about $659,000. Finally, Key Square Capital Management LLC purchased a new position in Translate Bio during the 2nd quarter valued at about $696,000. 40.88% of the stock is currently owned by institutional investors and hedge funds.
About Translate Bio
Translate Bio, Inc, a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency.
See Also: Risk Tolerance
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.